Published in J Natl Cancer Inst on April 06, 1994
Evaluation of Long Term Immunity Following HPV Vaccination | NCT02276521
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 4.14
Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol (1995) 2.46
Interaction of papillomaviruses with the cell surface. J Virol (1994) 2.44
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
The epidemiology of conjunctival squamous cell carcinoma in Uganda. Br J Cancer (2002) 2.18
Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol (1995) 2.13
Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clin Diagn Lab Immunol (2003) 1.95
Binding and internalization of human papillomavirus type 33 virus-like particles by eukaryotic cells. J Virol (1995) 1.70
Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA. J Infect Dis (2014) 1.58
Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer (2003) 1.55
Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res (2010) 1.50
Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol (1998) 1.49
Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica. Br J Cancer (2004) 1.40
Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol (2002) 1.35
Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin Diagn Lab Immunol (1997) 1.34
Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor. J Virol (1995) 1.32
Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci U S A (1999) 1.31
Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J Virol (2003) 1.27
Enhanced enzyme-linked immunosorbent assay for detection of antibodies to virus-like particles of human papillomavirus. J Clin Microbiol (2002) 1.22
Detection and quantitation of human papillomavirus by using the fluorescent 5' exonuclease assay. J Clin Microbiol (1999) 1.21
Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes. J Clin Microbiol (2001) 1.17
Differences in history of sexual behavior between patients with oropharyngeal squamous cell carcinoma and patients with squamous cell carcinoma at other head and neck sites. Head Neck (2010) 1.16
The use of human papillomavirus seroepidemiology to inform vaccine policy. Sex Transm Dis (2009) 1.14
Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. Br J Cancer (2011) 1.13
Papillomaviruses: Viral evolution, cancer and evolutionary medicine. Evol Med Public Health (2015) 1.13
Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J Virol (2003) 1.11
Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinoma. Cancer Res (2010) 1.09
Prospective seroepidemiological evidence that human papillomavirus type 16 infection is a risk factor for oesophageal squamous cell carcinoma. BMJ (1995) 1.09
Optimization of a human papillomavirus-specific enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol (2002) 1.02
Detection of antibodies against human papillomavirus (HPV) type 16 virions by enzyme-linked immunosorbent assay using recombinant HPV 16 L1 capsids produced by recombinant baculovirus. J Clin Microbiol (1995) 1.01
Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer. J Virol (2005) 1.00
Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA. Genitourin Med (1997) 0.99
Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers. J Virol (2005) 0.98
Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes. Virology (2009) 0.98
Combined p53-related genetic variants together with HPV infection increase oral cancer risk. Int J Cancer (2011) 0.96
Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination. Clin Exp Immunol (2007) 0.96
Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites. Br J Cancer (2003) 0.95
Role of human papillomavirus types 16, 18, and 52 in recurrent cystitis and urinary bladder cancer among Egyptian patients. Medscape J Med (2008) 0.95
Interlaboratory agreement among results of human papillomavirus type 16 enzyme-linked immunosorbent assays. J Clin Microbiol (1997) 0.95
Human papillomavirus-specific antibody status in oral fluids modestly reflects serum status in human immunodeficiency virus-positive individuals. Clin Diagn Lab Immunol (2003) 0.95
Papillomavirus capsids: a new approach to identify serological markers of HPV infection. J Natl Cancer Inst (1994) 0.92
Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. Carcinogenesis (2008) 0.92
Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Clin Vaccine Immunol (2015) 0.92
Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice. J Immunol (2006) 0.90
p73 G4C14-to-A4T14 polymorphism and risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never smokers and never drinkers. Cancer (2008) 0.90
Use of the normalized absorbance ratio as an internal standardization approach to minimize measurement error in enzyme-linked immunosorbent assays for diagnosis of human papillomavirus infection. J Clin Microbiol (2010) 0.90
Comparison of different assays to assess human papillomavirus (HPV) type 16- and 18-specific antibodies after HPV infection and vaccination. Clin Vaccine Immunol (2013) 0.90
New Approaches to Immunotherapy for HPV Associated Cancers. Cancers (Basel) (2011) 0.89
Immunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection. Sex Transm Infect (1998) 0.89
A prospective study of the relationship between prediagnostic human papillomavirus seropositivity and HPV DNA in subsequent cervical carcinomas. Br J Cancer (2002) 0.87
Monitoring of human papillomavirus vaccination. Clin Exp Immunol (2010) 0.86
Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses. J Clin Microbiol (2003) 0.86
Arsenic exposure and human papillomavirus response in non-melanoma skin cancer Mexican patients: a pilot study. Int Arch Occup Environ Health (2004) 0.85
Projected impact of Cervarix™ vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom. Hum Vaccin Immunother (2016) 0.83
A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome. Vaccine (2010) 0.83
MicroRNA variants increase the risk of HPV-associated squamous cell carcinoma of the oropharynx in never smokers. PLoS One (2013) 0.82
Serological relationship between cutaneous human papillomavirus types 5, 8 and 92. J Gen Virol (2009) 0.82
Modifying effect of MDM4 variants on risk of HPV16-associated squamous cell carcinoma of oropharynx. Cancer (2011) 0.82
Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA. J Clin Microbiol (1996) 0.82
Prospective study on cervical neoplasia: presence of HPV DNA in cytological smears precedes the development of cervical neoplastic lesions. Sex Transm Infect (2003) 0.81
Laboratory and clinical aspects of human papillomavirus testing. Crit Rev Clin Lab Sci (2012) 0.80
Evidences suggesting involvement of viruses in oral squamous cell carcinoma. Patholog Res Int (2013) 0.80
Self-assembly of in vitro-translated human papillomavirus type 16 L1 capsid protein into virus-like particles and antigenic reactivity of the protein. Clin Diagn Lab Immunol (1996) 0.79
Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination. Sex Transm Infect (2000) 0.79
Detection of infectious organisms in archival prostate cancer tissues. BMC Cancer (2014) 0.79
Chimeric recombinant rotavirus-like particles as a vehicle for the display of heterologous epitopes. Virol J (2009) 0.78
Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies. Clin Vaccine Immunol (2012) 0.78
Biomarkers of head and neck cancer, tools or a gordian knot? Int J Clin Exp Med (2015) 0.78
Human papillomavirus seropositivity and subsequent risk of HIV acquisition in rural South African women. Sex Transm Dis (2013) 0.77
Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids. Br J Cancer (2016) 0.77
Role of human papillomavirus in the pathogenesis of oral squamous cell carcinoma. World J Exp Med (2012) 0.77
Genetic variants of NOXA and MCL1 modify the risk of HPV16-associated squamous cell carcinoma of the head and neck. BMC Cancer (2012) 0.76
HPV Serology Testing Confirms High HPV Immunisation Coverage in England. PLoS One (2016) 0.75
Genetic variants of a BH3-only pro-apoptotic gene, PUMA, and risk of HPV16-associated squamous cell carcinoma of the head and neck. Mol Carcinog (2011) 0.75
Effect of human papillomavirus seropositivity and E2F2 promoter variants on risk of squamous cell carcinomas of oropharynx and oral cavity. Carcinogenesis (2016) 0.75
Role of histological findings and pathologic diagnosis for detection of human papillomavirus infection in men. J Med Virol (2015) 0.75
Comparisons of VLP-Based ELISA, Neutralization Assays with Native HPV, and Neutralization Assays with PsV in Detecting HPV Antibody Responses in HIV-Infected Women. J AIDS Clin Res (2015) 0.75
Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females. Exp Ther Med (2017) 0.75
A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A (1983) 14.73
Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst (1993) 9.48
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A (1992) 7.72
Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol (1992) 7.14
Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA (1991) 6.83
A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med (1992) 5.96
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol (1993) 5.12
The Papanicolaou test for cervical cancer detection. A triumph and a tragedy. JAMA (1989) 4.23
Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol (1993) 4.00
Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk. Lancet (1993) 2.58
High prevalence of papillomavirus-associated penile intraepithelial neoplasia in sexual partners of women with cervical intraepithelial neoplasia. N Engl J Med (1987) 2.37
Comparison of neutralization of BPV-1 infection of C127 cells and bovine fetal skin xenografts. Int J Cancer (1991) 1.98
Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst (1989) 1.72
Transcriptional differences of the human papillomavirus type 16 genome between precancerous lesions and invasive carcinomas. J Virol (1988) 1.63
Determinants of genital human papillomavirus infection among cytologically normal women attending the University of New Mexico student health center. Sex Transm Dis (1993) 1.57
Screening errors in cervical cytologic screening. Acta Cytol (1987) 1.35
Cervical papillomavirus infection and cervical dysplasia in Hispanic, Native American, and non-Hispanic white women in New Mexico. Am J Public Health (1991) 1.29
Humoral assays of human sera to disrupted and nondisrupted epitopes of human papillomavirus type 1. Virology (1990) 1.25
HPV-1 capsids expressed in vitro detect human serum antibodies associated with foot warts. Virology (1993) 1.25
Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions. J Gen Virol (1992) 1.24
Serological assays for the detection of HPV antibodies. IARC Sci Publ (1992) 1.18
Use of human papillomavirus type 11 virions in an ELISA to detect specific antibodies in humans with condylomata acuminata. J Gen Virol (1991) 1.09
Validation of hybridization assays: correlation of filter in situ, dot blot and PCR with Southern blot. IARC Sci Publ (1992) 1.04
Mechanism of activation of a human oncogene. Nature (1982) 12.09
Improved amplification of genital human papillomaviruses. J Clin Microbiol (2000) 11.50
Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol (1998) 9.43
Mouse cells transformed by bovine papillomavirus contain only extrachromosomal viral DNA sequences. Proc Natl Acad Sci U S A (1981) 9.27
Murine leukemia virus: high-frequency activation in vitro by 5-iododeoxyuridine and 5-bromodeoxyuridine. Science (1971) 8.78
The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature (1981) 8.44
Helper-independent transformation by unintegrated Harvey sarcoma virus DNA. J Virol (1978) 7.75
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A (1992) 7.72
A quantitative in vitro focus assay for bovine papilloma virus. Virology (1980) 7.14
In vitro tumorigenic transformation by a defined sub-genomic fragment of bovine papilloma virus DNA. Nature (1980) 6.67
HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J (1989) 6.60
Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med (2001) 6.33
Identification of a second transforming region in bovine papillomavirus DNA. Proc Natl Acad Sci U S A (1984) 5.88
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet (2009) 5.68
Bovine papillomavirus E2 trans-activating gene product binds to specific sites in papillomavirus DNA. Nature (1987) 5.61
Analysis of two divergent rat genomic clones homologous to the transforming gene of Harvey murine sarcoma virus. Proc Natl Acad Sci U S A (1981) 5.51
Cellular origin and role of mink cell focus-forming viruses in murine thymic lymphomas. Nature (1982) 5.23
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol (1993) 5.12
Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature (1982) 5.08
Transfection of molecularly cloned Friend murine leukemia virus DNA yields a highly leukemogenic helper-independent type C virus. J Virol (1980) 4.91
Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis (1994) 4.89
Molecular cloning of infectious integrated murine leukemia virus DNA from infected mouse cells. Proc Natl Acad Sci U S A (1980) 4.71
Dual evolutionary origin for the rat genetic sequences of Harvey murine sarcoma virus. J Virol (1980) 4.63
Origin of mink cytopathic focus-forming (MCF) viruses:comparison with ecotropic and xenotropic murine leukemia virus genomes. Virology (1981) 4.62
Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. Science (1988) 4.58
Virus-specific transcription in bovine papillomavirus-transformed mouse cells. Virology (1982) 4.52
Qualitative and quantitative studies of AKR-type murine leukemia virus sequences in mouse DNA. Cold Spring Harb Symp Quant Biol (1975) 4.49
The p21 ras C-terminus is required for transformation and membrane association. Nature (1984) 4.43
Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO J (1984) 4.28
Structure of endogenous murine leukemia virus DNA in mouse genomes. Proc Natl Acad Sci U S A (1980) 4.24
Genomes of murine leukemia viruses isolated from wild mice. J Virol (1981) 4.24
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 4.14
Long terminal repeat of murine retroviral DNAs: sequence analysis, host-proviral junctions, and preintegration site. J Virol (1982) 4.06
E5 open reading frame of bovine papillomavirus type 1 encodes a transforming gene. J Virol (1986) 4.04
Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science (1987) 3.93
Molecular cloning of the Harvey sarcoma virus closed circular DNA intermediates: initial structural and biological characterization. J Virol (1979) 3.90
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol (1996) 3.66
Virus infection of murine teratocarcinoma stem cell lines. Cell (1977) 3.54
Definitive evidence that the murine C-type virus inducing locus Akv-1 is viral genetic material. Proc Natl Acad Sci U S A (1975) 3.51
Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses. Proc Natl Acad Sci U S A (1982) 3.48
Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell (1992) 3.30
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 3.28
Characterization of a human colon/lung carcinoma oncogene. Nature (1983) 3.26
Identification of the protein encoded by the E6 transforming gene of bovine papillomavirus. Science (1985) 3.21
Determinants of genital human papillomavirus detection in a US population. J Infect Dis (2001) 3.21
The transforming function of bovine papillomavirus DNA. Proc Natl Acad Sci U S A (1983) 3.19
Translation of open reading frame E5 of bovine papillomavirus is required for its transforming activity. Proc Natl Acad Sci U S A (1986) 3.17
Mammalian and yeast ras gene products: biological function in their heterologous systems. Science (1985) 3.03
Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. J Virol (1989) 3.01
Evidence that the AKR murine-leukemia-virus genome is complete in DNA of the high-virus AKR mouse and incomplete in the DNA of the "virus-negative" NIH mouse. Proc Natl Acad Sci U S A (1974) 2.95
AKR murine leukemia virus genome: frequency of sequences in DNA of high-, low-, and non-virus-yielding mouse strains. Proc Natl Acad Sci U S A (1974) 2.91
Nucleotide sequence of the 3' end of MCF 247 murine leukemia virus. J Virol (1983) 2.87
Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. EMBO J (1987) 2.84
Mutational analysis of a ras catalytic domain. Mol Cell Biol (1986) 2.76
The specific DNA recognition sequence of the bovine papillomavirus E2 protein is an E2-dependent enhancer. EMBO J (1988) 2.66
The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J (1990) 2.57
The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF and CSF-1 receptors. Cell (1989) 2.52
Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J Virol (1994) 2.52
Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol (1995) 2.46
Functional organization of the Harvey murine sarcoma virus genome. J Virol (1980) 2.46
Interaction of papillomaviruses with the cell surface. J Virol (1994) 2.44
The E7 open reading frame of human papillomavirus type 16 encodes a transforming gene. Oncogene Res (1988) 2.42
Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol (1997) 2.40
High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev (2001) 2.38
Novel structural features of bovine papillomavirus capsid revealed by a three-dimensional reconstruction to 9 A resolution. Nat Struct Biol (1997) 2.30
Bovine papilloma virus-transformed cells contain multiple E2 proteins. Proc Natl Acad Sci U S A (1988) 2.29
Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol (2001) 2.28
Restriction endonuclease mapping of ecotropic murine leukemia viral DNAs: size and sequence heterogeneity of the long terminal repeat. Virology (1981) 2.25
Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology (2000) 2.25
Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol (1998) 2.21
A causal role for human papillomavirus in head and neck cancer. Lancet (2004) 2.21
Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol (1995) 2.13
Genital human papillomavirus infection. Proc Natl Acad Sci U S A (1994) 2.12